Form 4: Director Serbin Boosts Co-Diagnostics Stake

Co-Diagnostics Director Richard S. Serbin reported the acquisition of 57,499 shares of common stock through the vesting of restricted stock units.

Summary

• Richard S. Serbin, a Director of Co-Diagnostics, Inc. (CODX), reported a change in beneficial ownership.
• On November 23, 2025, Serbin acquired 57,499 shares of common stock at a price of $0.00 per share.
• This acquisition resulted from the scheduled vesting of multiple restricted stock unit (RSU) awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
• Following this transaction, Serbin directly beneficially owns 271,666 shares of common stock.
• The filing also indicates 170,834 derivative securities (RSUs) are beneficially owned directly after the transaction, with 228,333 shares of common stock underlying these derivative securities.

Sentiment

Score: 7

Explanation: The filing indicates a routine, pre-scheduled vesting of equity compensation for a director, which is generally a neutral to slightly positive event as it increases insider ownership without an open market purchase, reflecting continued alignment with company performance.

Positives

• Director Richard S. Serbin increased his direct beneficial ownership of Co-Diagnostics common stock by 57,499 shares, indicating continued alignment with shareholder interests.
• The acquisition was due to the scheduled vesting of restricted stock units, a non-cash event that typically reflects long-term incentive compensation and retention.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it aligns director interests with long-term company performance.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled vesting of restricted stock units for a director, which increases their beneficial ownership. While it shows continued alignment of interests, it does not represent an open market purchase or sale based on new information, nor does it provide new fundamental data to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as this event alone is unlikely to significantly impact the stock's valuation or future prospects.

Keywords

Co-Diagnostics, CODX, Richard Serbin, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Ownership, Equity Compensation